title: [Investigation on the alteration of hepatitis B virus (HBV) markers in liver allograft of HBV related recipients in perioperative period].
abstract: OBJECTIVE
  To investigate the alteration of HBV markers in liver allograft of HBV related recipients pre and post liver transplantation under Lamivudine or combination of Lamivudine with HBIG prophylaxis and explore the mechanism of HBV de nova infection in liver allograft after orthotopic liver transplantation, as well as seek to establish a optimal prophylactic protocol.
  
  
  METHODS
  The serial liver biopsy specimens of 90 liver allograft and sera of 78 liver transplant recipients during operation and after 1 week, 1 month, 3 months, 6 months, 12 months, 24 months post transplantation have been collected and detected for HBV markers with enzyme-linked radioimmunoassay, fluorescent quantitative assay for HBV-DNA in serology and with immunohistochemistry stain, HBV-DNA in situ hybridization in histology for detection of HBV markers in liver allograft samples.
  
  
  RESULTS
  Whether recipients with active replicative or inactive replicative HBV preoperatively, none of positive HBV-DNA, HBsAg and HBcAg in 100% liver biopsy specimens with HBV-DNA hybridization in situ and immunohistochemistry stains in histology within 2 hours after reperfusion.
  
  
  CONCLUSIONS
  Whatever HBV replicative status the recipients have before surgery, no evidence of HBV particles direct invasion to the liver allograft from HBV related cirrhotics during operation under current prophylactic measures. However, the further supposed mechanism and its significance in HBV de nova infection of liver allograft remained to be disclosed further.
authors.affiliation: West China Liver Transplantation Center, West China Hospital, Sichuan University, Chengdu 610041, China.
authors.forename: Jun
authors.initials: J
authors.lastname: Dai
authors.forename: Shi-chun
authors.initials: SC
authors.lastname: Lu
authors.forename: Lv-nan
authors.initials: LN
authors.lastname: Yan
authors.forename: Bo
authors.initials: B
authors.lastname: Li
authors.forename: Wen
authors.initials: W
authors.lastname: Lai
authors.forename: Jun
authors.initials: J
authors.lastname: Liu
authors.forename: Ji
authors.initials: J
authors.lastname: Zhao
authors.forename: Tian-fu
authors.initials: TF
authors.lastname: Wen
authors.forename: Mei
authors.initials: M
authors.lastname: Gui
authors.forename: Qi-yuan
authors.initials: QY
authors.lastname: Lin
authors.forename: Wen-ya
authors.initials: WY
authors.lastname: Wang
authors.forename: Xiu-hui
authors.initials: XH
authors.lastname: Zhang
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D015415:Biomarkers / Q000097:blood; D002648:Child; D004279:DNA, Viral / Q000097:blood; D005260:Female; D006511:Hepatitis B Antigens / Q000097:blood*; D006514:Hepatitis B Surface Antigens / Q000097:blood; D006513:Hepatitis B e Antigens / Q000097:blood; D006515:Hepatitis B virus / Q000235:genetics / Q000254:growth & development*; D019694:Hepatitis B, Chronic / Q000175:diagnosis / Q000188:drug therapy / Q000601:surgery*; D006801:Humans; D007116:Immunization, Passive; D007136:Immunoglobulins / Q000008:administration & dosage; D019259:Lamivudine / Q000627:therapeutic use; D016031:Liver Transplantation; D008297:Male; D008875:Middle Aged; D011300:Preoperative Care / Q000379:methods; D055502:Secondary Prevention
chemical_list: D015415:Biomarkers; D004279:DNA, Viral; D006511:Hepatitis B Antigens; D006514:Hepatitis B Surface Antigens; D006513:Hepatitis B e Antigens; D007136:Immunoglobulins; D019259:Lamivudine; C045213:hepatitis B hyperimmune globulin